Free Trial
Thomas Smith

Thomas Smith Analyst Performance

Senior Managing Director, Biotechnology Analyst at Leerink Partners

Thomas Smith is a stock analyst at Leerink Partners focused in the medical sector, covering 14 publicly traded companies. Over the past year, Thomas Smith has issued 7 stock ratings, including and buy recommendations. While full access to Thomas Smith's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Thomas Smith's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
14 Last 5 Years
Buy Recommendations
71.43% 10 Buy Ratings
Companies Covered
14 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy71.4%10 ratings
Hold28.6%4 ratings
Sell0.0%0 ratings

Out of 14 total stock ratings issued by Thomas Smith at Leerink Partners, the majority (71.4%) have been Buy recommendations, followed by 28.6% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
92.9% of companies on NASDAQ
13 companies
NYSE
7.1% of companies on NYSE
1 company

Thomas Smith, an analyst at Leerink Partners, currently covers 14 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
12 companies
85.7%
Manufacturing
2 companies
14.3%

Thomas Smith of Leerink Partners specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
10 companies
71.4%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
1 company
7.1%
Miscellaneous
1 company
7.1%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
7.1%
BIOTECHNOLOGY
1 company
7.1%

Thomas Smith's Ratings History at Leerink Partners

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
4/13/2026Boost Price Target$63.06$106.00Outperform
AgomAb Therapeutics NV stock logo
AGMB
AgomAb Therapeutics
3/3/2026Initiated Coverage$16.21$36.00Outperform
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
1/12/2026Initiated Coverage$4.83$12.00Outperform
Alumis Inc. stock logo
ALMS
Alumis
1/6/2026Boost Price Target$16.23$32.00Outperform
Evommune, Inc. stock logo
EVMN
Evommune
12/1/2025Initiated Coverage$20.71$42.00Outperform
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
9/26/2025Upgrade$24.45$37.00Outperform
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
7/23/2025Set Price Target$65.45$74.00Outperform
Equillium, Inc. stock logo
EQ
Equillium
3/28/2025Reiterated Rating$0.49$1.00Market Perform